Fusion protein delivery systems and uses thereof

Details Fusion protein delivery systems and uses thereof Fusion protein delivery systems and uses thereof

1997-09-29

1999-12-14

Degen, Nancy

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

4353201, 435367, C07H 2104

Patent

active

060019859

ABSTRACT:
The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a virus inhibitory protein. In another embodiment of the present invention, there is provided a composition of matter, comprising: DNA encoding a viral Vpr protein fused to DNA encoding a virus inhibitory protein. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.

REFERENCES:
patent: 5175099 (1992-12-01), Wills
patent: 5378806 (1995-01-01), Willis
patent: 5861161 (1999-01-01), Cohen et al.
Wu et al. The First National Conference on Human Retroviruses and Related Infections. Washington, DC., 1993.
Percy et al., "A poliovirus replicon containing the chloramphenicol acetyltransferase gene can be used to study the replication and encapsidation of poliovirus RNA", J. Virol. 66(8):5040-5046, Aug. 1992.
Hu et al., "Analysis and function of viral protein X (VPX) of HIV-2", Virol. 173: 624-630, 1989.
Zhao et al., "Biochem. Mechanism of HIV-1 Vpr function", J. Biol. Chem. 269: 15577-15582, Jun. 1994.
Natsoulis et al., Targeting of a nuclease to murine leukemia virus capsids inhibit viral multiplication, Proc. Natl. Acad. Sci. USA 92:364-368, Jan. 1995.
Natsoulis and Boeke, "New antiviral strategy using capsid-nuclease fusion proteins", Nature 352: 632-635, Aug. 1991.
Wu et al., "Targeting foreign proteins to human immunodeficiency viruses types 1 and 2 via fusion with Vpr and Vpx", Biol. Abstr./RRM 47(4): MT-323, Ref. No. 66007, Jan. 1995.
Wu et al., "Inhibition of HIV-1 replication by targeting Vpr fusion proteins to virions", Biol. Abstr./RRM 47(4): MT-323, Ref. No. 66020, Jan. 1995.
Kappes et al, "The HIV Vpx and Vpr genes mediate virion incorporation of nuclease fusion proteins", J. Biol. Chem. Suppl. 21(A): 162, Ref. No. J513, Jan. 1994.
Kappes et al., "Targeting foreign proteins to HIV particles via fusion with Vpr and Vpx", J. Biol. Chem. Suppl. 21(A): 395, Ref. No. C6-328, Mar. 1995.
Wu et al. "HIV/SIV Virion Associated Accessory Genes Mediate Efficient Packaging of Nuclease Fusion Proteins Into The Virus Particle," The First National Conference on Human Retroviruses and Related Infections, Washington DC (1993).
Kappes et al. "Intracellular Transport And Virion Incorporation of vpx Requires Interaction With Other Virus Type-Specific Components," J. Virol. 193: 222-223 (1993).
Wu et al. "Targeting Foreign Proteins To Human Immunodeficiency Virus Particles Via Fusion With Vpr and Vpx," (Revised Manuscript, #JVI 1529-94), J. Virology, vol. 69, pp. 3389-3398 (1995).
Orkin et al. "Report And Recommendations Of The Panel To Assess The NIH Investment In Research On Gene Therapy," NIH Panel Report, Dec. 1995. Entire Report.
Tristem et al. "Evolution Of the Primate Lentiviruses: Evidence From Vpx and Vpr," EMBO J 11:3405-3412 (1992).
Tristem et al. "Origin Of Vpx In Lentiviruses," Nature 347:341-342.39 (1990).
Wu et al. "Inhibition Of Human And Simian Immunodeficiency Virus Protease Function By Targeting Vpx-Protease-Mutant Fusion Protein Into Viral Particles," J. Virol. 3378-3384 (Jun. 1996).
Liu et al. "Incorporation Of Functional Human Immunodeficiency Virus Type 1 Integrase Into Virions Independent Of The Gag/Pol Precursor Protein," (Revised Manuscript, #JVI 548-97) J. Virology, vol. 71, pp. 7704-7710 (1997).
Wu et al. "Functional RT and IN Incorporated Into HIV-1 Particles Independent Of The Gag/Pol Precursor Protein," EMBO J 16: 0, 101-109 (1997).
Lee et al. "The role of vpx in the life cycle of HIV-2," submitted to the Proceedings of the Third Annual "Colloque Des Cent Gardes" (1988).
Kappes et al. "Human Immunodeficiency Virus Type 2 vpx Protein Augments Viral Infectivity," Virology, 184, 197-209 (1991).
Kappes et al. "Identification of a Novel Retroviral Gene Unique to Human Immunodeficiency Virus Type 2 and Simian Immunodeficiency Virus SIV.sub.MAC, " vol. 62, No. 9, pp. 3501-3505 (Sep. 1988).
Wu et al. "Localization of the Vpx Packaging Signal within the C Terminus of the Human Immunodeficiency Virus Type 2 Gag Precursor Protein," J. Virol., vol. 68, No. 10, pp. 6161-6169 (Oct. 1994).
Akari et al. "Biological characterization of human immunodeficiency virus type 1 and type 2 mutants in human peripheral blood mononuclear cells," Arch. Virol. (1992) 123: 157-167.
Balotta et al. "Antisense Phosphorothioate Oligodeoxynucleotides Targeted to the vpr Gene Inhibit Human Immunodeficiency Virus Type 1 Replication in Primary Human Macrophages," J. Virol., vol. 67, No. 7, pp. 4409-4414 (Jul. 1993).
Cohen et al. "Human Immunodeficiency Virus vpr Product Is a Virion-Associated Regulatory Protein," J. Virol., vol. 64, No. 6, pp. 3097-3099 (Jun. 1990).
Dedera et al. "Viral Protein R of Human Immunodeficiency Virus Types 1 and 2 Is Dispensable for Replication and Cytopathogenicity in Lymphoid Cells," J. Virol., vol. 63, No. 7, pp. 3205-3208 (Jul. 1989).
Desrosiers. "HIV with Multiple Gene Deletions as a Live Attenuated Vaccine for AIDS," AIDS Research and Human Retroviruses, vol. 8, No. 3, pp. 411-421 (Nov. 3, 1992).
Di Marzio et al. "Mutational Analysis of Cell Cycle Arrest, Nuclear Localization, and Virion Packaging of Human Immunodeficiency Virus Type 1 Vpr," J. Virol., vol. 69, No. 12, pp. 7909-7916 (Dec. 1995).
Gibbs et al. Construction and In Vitro Properties of SIV.sub.mac Mutants with Deletions in "Nonessential" Genes, AIDS Research and Human Retroviruses, vol. 10, No. 5, pp. 607-616 (Nov. 5, 1994).
Gibbs et al. "Progression to AIDS in the Absence of a Gene for vpr or vpx," J. Virol., vol. 69, No. 4, pp. 2378-2383 (Apr. 1995).
Guyader et al. "VPX mutants of HIV-2 are infectious in established cell lines but display a severe defect in peripheral blood lymphocytes," The EMBO Journal, vol. 8, No. 4, pp. 1169-1175 (1989).
Zhao et al. "Biochemical Mechanism of HIV-1 Vpr Function: Oligomerization Mediated by the N-Terminal Domain," J. Biol. Chem. 269, pp. 32131-32137 (Dec. 1994).
He et al. "Human Immunodeficiency Virus Type 1 Viral Protein R (Vpr) Arrests Cells in the G.sub.2 Phase of the Cell Cycle by Inhibiting p34.sup.cdc2 Activity," J. Virol., vol. 69, No. 11, pp. 6705-6711 (Nov. 1995).
Heinzinger et al. "The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells," Proc. Natl. Acad. Sci. USA, vol. 91, pp. 7311-7315 (Jul. 1994).
Hoch et al. "vpr Deletion Mutant of Simian Immunodeficiency Virus Induces AIDS in Rhesus Monkeys," J. Virol., vol. 69, No. 8, pp. 4807-4813 (Aug. 1995).
Horton et al. "HIV-2 Viral Protein X Association with the Gag p27 Capsid Protein," Virology 199, 453-457 (1994).
Kewalramani et al. "Vpx Association with Mature Core Structures of HIV-2," Virology 218, 159-168 (1996).
Kewalramani et al. "Protein Stability Influences Human Immunodeficiency Virus Type 2 Vpr Virion Incorporation and Cell Cycle Effect," Virology 218, 326-334 (1996).
Kirchhoff et al. "Upstream U3 Sequences in Simian Immunodeficiency Virus Are Selectively Deleted In Vivo in the Absence of an Intact nef Gene," J. Virol., vol. 68, No. 3, pp. 2031-2037 (Mar. 1994).
Kondo et al. "The p6.sup.gag Domain of Human Immunodeficiency Virus Type 1 Is Sufficient for the Incorporation of Vpr into Heterologous Viral Particles," J. Virol., vol. 69, No. 5, pp. 2759-2764 (May 1995).
Lang et al. "Importance of vpr for Infection of Rhesus Monkeys with Simian Immunodeficiency Virus," J. Virol., vol. 67, No. 2, pp. 902-912 (Feb. 1993).
Lavallee et al. "Requirement of the Pr55.sup.gag Precursor for Incorporation of the Vpr Product into Human Immunodeficiency Virus Type 1 Viral Particles," J. Virol., vol. 68, No. 3, pp. 1926-1934 (Mar. 1994).
Levy et al. "Extracellular Vpr Protein Increases Cellular Permissiveness to Human Immunodeficiency Virus Replication and Reactivates Virus from Latency," J. Virol., vol. 69, No. 2, pp. 1243-1252 (Feb. 1995).
Levy et al. "Induction of Cell Differentiation by Human Immunodeficiency Virus 1 vpr," Cell, vol. 72, 541-550 (Feb. 26, 1993).
Levy et al. "Serum Vpr regulates productive infection and l

Affiliated with

Also associated with

Rating

Fusion protein delivery systems and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fusion protein delivery systems and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion protein delivery systems and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-864721